Trimbow – Evidence Summary
Trimbow pMDI 87/5/9 is indicated for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.1
Beclometasone given by inhalation is a corticosteroid with glucocorticoid anti-inflammatory action which suppresses inflammation in the lungs.
Formoterol is a selective β2-adrenergic agonist that produces relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect sets in rapidly, within 1–3 minutes after inhalation, and has a duration of 12 hours after a single dose.
Glycopyrronium is a high-affinity, long-acting muscarinic receptor antagonist (anticholinergic) resulting in a bronchodilator effect on the lungs.
Trimbow pMDI 87/5/9 Clinical Trial[]
TRIMARAN was a randomised (1:1), double-blind, multinational, active-controlled 2-arm parallel group study2
TRIMARAN study design overview2
|Aim||Compared Trimbow pMDI 87/5/9 2 puffs b.d. with medium dose Fostair (beclometasone/formoterol) pMDI 100/6 2 puffs b.d. in patients with asthma that were poorly controlled on medium-dose ICS/LABA therapy|
|Duration||52-week treatment period|
● Pre-dose morning FEV1 at week 26
● Rate of moderate and severe exacerbations over 52 weeks
TRIMARAN study key results
- 15% reduction in rate of moderate and severe exacerbations vs. Fostair pMDI 100/6 (Annualised rate: 1.83 vs. 2.16 respectively [ARR 0.33, RR 0.85, p=0.033])2
- 57 mL improvement in pre-dose morning FEV1 vs. Fostair pMDI 100/6 (Change from baseline: 185 mL vs. 127 mL respectively [p=0.008])2
Safety and tolerability[]
TRIMARAN study safety and tolerability2